Published in Healthcare Finance, Tax and Law Weekly, June 15th, 2005
The addition of the NBU strengthens PRA's central nervous system (CNS) global clinical development services, which includes, in-house study design consulting, regulatory expertise, a global investigator network, long-standing relationships with key opinion leaders, and study-specific investigator training.
Wendy L. Martin, MD, vice president, global product development services - CNS, said PRA established the NBU specifically to meet the growing demand for expert guidance in the selection of screening and outcome measures for compounds.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.